Biomaterials is an Elsevier journal for materials designed for biological and medical
application: tissue engineering and regenerative scaffolds, drug and gene delivery,
implants and coatings, and biointerfaces. Its defining demand is dual rigor — a
submission must combine thorough materials design and characterization with genuine
biological evaluation (in vitro and/or in vivo), and the two must be tied together by a
mechanism: how the material's properties produce the biological outcome. A strong
materials paper carrying only a token cell-viability assay, or a biology study using an
off-the-shelf material with no materials advance, is a poor fit. This skill is a fit
/ venue-selection / re-framing tool. It does not replace the journal's current
official author guidelines. Before submitting, re-check the live Biomaterials Guide for
Authors on the Elsevier site.
When to trigger
The author names Biomaterials for a tissue-engineering, delivery, implant, or
biointerface manuscript and wants a fit/framing and dual-rigor check.
A materials paper must be re-framed to add — and mechanistically connect — meaningful
biological evaluation, or a biology paper must show a real materials advance.
The author is choosing between Biomaterials, nature-biomedical-engineering, and the
functional-materials family (advanced-materials, nature-materials).
The author needs the journal's biological-evaluation bar and its desk-reject
heuristics.
Scope & topic fit
Tissue engineering and regenerative medicine: scaffolds, hydrogels, and engineered
matrices where material design drives a demonstrated cell/tissue response.
Drug, gene, and cell delivery: carriers and depots characterized as materials and
evaluated for loading, release, targeting, and biological efficacy.
Implants, devices, and coatings: degradable and load-bearing materials with
characterized properties and biological/host response.
Biointerfaces and surface engineering: surface chemistry/topography linked
mechanistically to protein adsorption, cell adhesion, or antifouling behavior.
Immunomodulatory, antibacterial, and bioactive materials where the biological effect
is traced to defined material properties.
Nano/micro-structured biomaterials when the materials advance and the biological
outcome are jointly established, not one without the other.
Method & evidence bar
The contribution must establish a material-property-to-biological-outcome
mechanism, not merely report that a new material is biocompatible.
Materials characterization must be thorough and appropriate: composition, structure,
mechanical and degradation behavior, and release/loading where relevant, with
quantitative, reproducible data.
Biological evaluation must be meaningful and matched to the claim: appropriate cell
types, relevant assays beyond a single viability test, and in-vivo validation where
the application demands it — with controls, adequate N, and statistics.
Properties and biological performance must be benchmarked against the correct
material/clinical baseline, not a strawman.
In-vivo work requires proper design (controls, randomization/blinding where
applicable, ethics approval) and honest reporting of limitations.
Reproducibility: material synthesis/processing, characterization protocols, and
biological methods reported in enough detail to reproduce both the material and the
measured response.
Structure & house style
Standard research-article structure (introduction, materials/methods, results,
discussion); Biomaterials publishes full-length archival articles — re-check current
article types and length on the live guide.
The introduction motivates the biomedical problem and the materials-design rationale
together; the discussion is where the structure–property–bioresponse mechanism is
argued explicitly.
Figures are load-bearing: materials characterization with quantification, and
biological data (imaging, assays, in-vivo outcomes) with controls, error bars, and
reported N and statistics.
Supplementary material carries extended characterization and full biological
protocols; main-text figures must support the central mechanism on their own.
Ethics and biosafety statements must be present where animal or human-derived material
is used.
Official-submission checklist
Before giving submission-ready advice, read ../../resources/source-basis.md and
../../resources/official-source-map.md; start from the Elsevier anchors, then cite
the current Biomaterials Guide for Authors page you checked.
Search the live site for "Biomaterials guide for authors" and follow the current
Elsevier/Editorial Manager version.
Re-check article types, length/figure expectations, and the data-availability policy.
Confirm ethics approval and animal-use (e.g., ARRIVE) reporting and any biosafety
requirements for in-vitro/in-vivo work.
Confirm graphical-abstract and highlights requirements if applicable.
Re-check competing-interests, funding, author-contribution (CRediT), and AI-use
disclosure requirements.
If the live official instructions conflict with this skill, the official instructions
win.
Pre-submission self-check
The paper establishes a material-property-to-biological-outcome mechanism, not just "biocompatible."
Materials characterization is thorough and quantitative (structure, mechanics, degradation, release as relevant).
Biological evaluation goes beyond a token viability assay, with appropriate cells/models, controls, N, and statistics.
In-vivo work (where the claim needs it) has proper design and ethics approval.
Properties and bioresponse are benchmarked against the correct material/clinical baseline.
Synthesis, characterization, and biological protocols are reported in reproducible detail.
Common desk-reject triggers
A materials paper with a token cell-viability assay and no biological insight or mechanism.
A biology study using an off-the-shelf material with no materials design or characterization advance.
"New biomaterial, it's biocompatible" with no structure–property–bioresponse mechanism.
Biological data with no controls, inadequate N, missing statistics, or absent ethics approval.
Performance benchmarked against a strawman rather than the correct material/clinical baseline.
Application-driven device paper where neither the materials nor the biology is advanced.
Re-routing decision
Engineering-/device-led biomedical advance with clinical translation focus → nature-biomedical-engineering.
Conceptual functional-materials advance with the materials science as the core → advanced-materials / nature-materials.
